Orion enters partnership with MSD, upgrades guidance
The US-based and Finnish firms will co-commercialize prostate cancer candidate ODM-208, and the deal has led Orion to raise its financial expectations.
by marketwire, translated by daniel pedersen
Pharmaceutical firm Orion has inked a deal with US-based MSD to co-develop and co-commercialize Orion’s prostrate cancer treatment candidate, ODM-208, the Finnish firm has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
MSD stops prostate cancer trial
For subscribers
